These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 18382225)

  • 1. Plasma biomarkers of Alzheimer's disease.
    Kawarabayashi T; Shoji M
    Curr Opin Psychiatry; 2008 May; 21(3):260-7. PubMed ID: 18382225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees.
    Ertekin-Taner N; Graff-Radford N; Younkin LH; Eckman C; Adamson J; Schaid DJ; Blangero J; Hutton M; Younkin SG
    Genet Epidemiol; 2001 Jul; 21(1):19-30. PubMed ID: 11443731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
    Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No correlation between time-linked plasma and CSF Abeta levels.
    Le Bastard N; Aerts L; Leurs J; Blomme W; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Dec; 55(8):820-5. PubMed ID: 19695299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
    Stuerenburg HJ; Ganzer S; Müller-Thomsen T
    Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease.
    Ait-ghezala G; Abdullah L; Volmar CH; Paris D; Luis CA; Quadros A; Mouzon B; Mullan MA; Keegan AP; Parrish J; Crawford FC; Mathura VS; Mullan MJ
    Cytokine; 2008 Nov; 44(2):283-7. PubMed ID: 18835787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Kester MI; Verwey NA; van Elk EJ; Scheltens P; Blankenstein MA
    Neurobiol Aging; 2010 Apr; 31(4):539-40; author reply 541. PubMed ID: 18963255
    [No Abstract]   [Full Text] [Related]  

  • 10. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease.
    Lewczuk P; Esselmann H; Groemer TW; Bibl M; Maler JM; Steinacker P; Otto M; Kornhuber J; Wiltfang J
    Biol Psychiatry; 2004 Mar; 55(5):524-30. PubMed ID: 15023581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease.
    Kuo YM; Emmerling MR; Lampert HC; Hempelman SR; Kokjohn TA; Woods AS; Cotter RJ; Roher AE
    Biochem Biophys Res Commun; 1999 Apr; 257(3):787-91. PubMed ID: 10208861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
    Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
    Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.
    Lui JK; Laws SM; Li QX; Villemagne VL; Ames D; Brown B; Bush AI; De Ruyck K; Dromey J; Ellis KA; Faux NG; Foster J; Fowler C; Gupta V; Hudson P; Laughton K; Masters CL; Pertile K; Rembach A; Rimajova M; Rodrigues M; Rowe CC; Rumble R; Szoeke C; Taddei K; Taddei T; Trounson B; Ward V; Martins RN; AIBL Research Group
    J Alzheimers Dis; 2010; 20(4):1233-42. PubMed ID: 20413897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.
    Fukumoto H; Tennis M; Locascio JJ; Hyman BT; Growdon JH; Irizarry MC
    Arch Neurol; 2003 Jul; 60(7):958-64. PubMed ID: 12873852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Abeta levels do not reflect brain Abeta levels.
    Freeman SH; Raju S; Hyman BT; Frosch MP; Irizarry MC
    J Neuropathol Exp Neurol; 2007 Apr; 66(4):264-71. PubMed ID: 17413317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.
    Xu W; Kawarabayashi T; Matsubara E; Deguchi K; Murakami T; Harigaya Y; Ikeda M; Amari M; Kuwano R; Abe K; Shoji M
    Brain Res; 2008 Jul; 1219():169-79. PubMed ID: 18534566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment.
    Pesaresi M; Lovati C; Bertora P; Mailland E; Galimberti D; Scarpini E; Quadri P; Forloni G; Mariani C
    Neurobiol Aging; 2006 Jun; 27(6):904-5. PubMed ID: 16638622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased amyloid beta protein levels in children and adolescents with Down syndrome.
    Mehta PD; Capone G; Jewell A; Freedland RL
    J Neurol Sci; 2007 Mar; 254(1-2):22-7. PubMed ID: 17275850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-based neurochemical diagnosis of vascular dementia: a pilot study.
    Bibl M; Esselmann H; Mollenhauer B; Weniger G; Welge V; Liess M; Lewczuk P; Otto M; Schulz JB; Trenkwalder C; Kornhuber J; Wiltfang J
    J Neurochem; 2007 Oct; 103(2):467-74. PubMed ID: 17662050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.